Sugi Predict

Sugi Predict / Compounds / SCHEMBL4415322

SCHEMBL4415322

SCHEMBL4415322

O=c1ccn([C@]2(OOBr)O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ SLC28A1 O00337 1/20 0.45
▸ SLC28A2 O43868 1/20 0.45
▸ SLC29A1 Q99808 1/20 0.45
▸ SLC28A3 Q9HAS3 1/20 0.45
▸ P2RY14 Q15391 8/20 0.40
▸ P2RY6 Q15077 8/20 0.36
▸ P2RY2 P41231 4/20 0.35
▸ P2RY4 P51582 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17627531 0.91 SLC28A1 (0.45) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL2168188 0.90 SLC28A1 (0.47) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL32670136 0.89 SLC28A1 (0.48) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL2635503 0.87 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL15226208 0.87 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL1044101 0.87 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL5494602 0.87 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
Phosphoric Acid SCHEMBL23611360 0.86 P2RY14 (0.44) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL15254113 0.86 SLC28A1 (0.42) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14
SCHEMBL17745010 0.85 SLC28A1 (0.44) SLC28A1SLC28A2SLC29A1SLC28A3P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0276287-B1 SEX DETERMINATION IN RUMINANTS USING Y-CHROMOSOME SPECIFIC POLYNUCLEOTIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1993-04-07 — — EP claimed
WO-1993004735-A1 METHOD AND APPARATUS FOR RESTENOSIS TREATMENT CEDARS-SINAI MEDICAL CENTER (US) 1993-03-18 — — WO claimed
US-8492145-B2 Process for producing nerve cells MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-07-23 — — US disclosed
WO-2012117387-A1 METHOD OF LABELING NEURONS AND ITS APPLICATION UNIVERSIDADE DO MINHO (PT) 2012-09-07 — — WO disclosed
EP-2131825-A1 MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-16 — — EP disclosed
WO-2008107373-A1 MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-12 — — WO disclosed
US-20050221479-A1 Process for producing nerve cells TANABE SEIYAKU CO., LTD. (JP) 2005-10-06 — — US disclosed
EP-1516926-A1 PROCESS FOR PRODUCING NERVE CELLS Tanabe Seiyaku Co., Ltd. (JP) 2005-03-23 — — EP disclosed
EP-0753313-B1 Skin substitute using marine organisms HOKKAIDO GOVERNMENT (JP) 2001-09-26 — — EP disclosed
US-5698228-A SHEET; LAMINATION; UNCROSSLINKED COLLAGEN HOKKAIDO GOVERNMENT (JP) 1997-12-16 — — US disclosed
EP-0753313-A1 Skin substitute using marine organisms Hokkaido Government (JP) 1997-01-15 — — EP disclosed
EP-0633786-A4 METHOD OF INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS. CRYOPHARM CORP (US) 1995-04-19 — — EP disclosed
EP-0633786-A1 METHOD OF INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS BAXTER INTERNATIONAL INC. (US) 1995-01-18 — — EP disclosed
WO-1993014791-A2 METHOD OF INACTIVATION OF VIRAL AND BACTERIAL BLOOD CONTAMINANTS CRYOPHARM CORPORATION (US) 1993-08-05 — — WO disclosed
WO-1993004735-A1 METHOD AND APPARATUS FOR RESTENOSIS TREATMENT CEDARS-SINAI MEDICAL CENTER (US) 1993-03-18 — — WO disclosed